Acute graft-versus-host disease of the skin research hub

Venetoclax as treatment of acute graft-versus-host disease in patients after allogeneic hematopoietic stem cell transplantation in a Phase-II dose escalation pilot study.

This study is testing a new medicine, Venclyxto, for people with a skin condition called acute graft-versus-host disease (aGVHD) after a stem cell transplant. It aims to find the safest and most effective dose.